Evidence map›Paper›PMID 38250859›Full record

ArticleVaccines2023

Performance of Human Gene EPB41L3 and HPV 16/18 Viral DNA Methylation to Triage hrHPV-Positive Women.

Remila Rezhake, Yan Wang, Xuelian Zhao, Marc Arbyn, Guqun Shen, Qinjing Pan, Xun Zhang, Yuanming Zhang, Fanghui Zhao, Youlin Qiao

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Remila RezhakeCancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Yan WangCancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Xuelian ZhaoDepartment of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Marc ArbynUnit of Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels B-1000, Belgium.ORCID 0000-0001-7807-5908
Guqun ShenCancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Qinjing PanDepartment of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xun ZhangDepartment of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Yuanming ZhangCancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.
Fanghui ZhaoDepartment of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Youlin QiaoCancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi 830000, China.ORCID 0000-0001-6380-0871
Xinjiang Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNSciensano (Belgium) · BE

Funding

China Medical Board 16 255China Postdoctoral Science Foundation 2021M6908National Natural Science Foundation of China 82260660Natural Science Foundation of Xinjiang 2021D01C379Postdoctoral Fund of Affiliated Cancer Hospital of Xinjiang Medical University 2021BSH-RML
6 · The paper itself

Abstract

More evidence from population-based cohort studies is required to confirm the application of methylation-based biomarkers in real-world settings. The cross-sectional and 24-month cumulative triage performance of a novel methylation assay targeting the host gene EPB41LE and HPV16/18 DNA L1/L2 regions among hrHPV-positive women was evaluated based on a population-based cohort study from China. Overall methylation positivity was 12.4% among hrHPV-positive women. Methylation-positive women had significantly higher risks of hrHPV persistence at 12M and 24M follow-up (RR

Indexed as

biomarkercancer screeningcervical cancerearly detectionHPVmethylationtriage

Identifiers

PMID38250859
PMCPMC10818390
OpenAlexW4390459109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.